TACSTD2 and neoplasm: Another tumor genomics study found 40% of breast NETs overexpressed topoisomerase-1, which is closely linked to TROP2 given that treatments that target TROP2 utilize a topoisomerase-1 inhibitor as the payload in the antibody-drug conjugate.9 These results suggest that some breast neuroendocrine cancers may have an amenable treatment response to TROP2 and topoisomerase-targeted treatments, such as SG.